October 28, 2013 — GE Healthcare announced that the somo•v Insight System was recognized as the category leader with the highest ranking in Women’s Imaging (Specialty) in the 2013 Best in KLAS Awards: Medical Equipment and Infrastructure Report. The Best in KLAS Awards Report ranked imaging, pharmacy automation and infrastructure vendors. This year, healthcare providers ranked over 180 products.
KLAS independently monitors vendor performance through the active participation of thousands of healthcare organizations. KLAS Performance Data represents the opinions of healthcare executives, managers and clinicians from over 4,500 hospitals and 2,500 clinics who have rated over 750 products and services from more than 200 vendors.
Using proprietary technology to automate the ultrasound imaging process, the somo•v automated breast ultrasound system (ABUS) system was developed specifically for the breast cancerscreening environment. Demonstrating a 35.7 percent improvement in cancer detection (sensitivity), the somo•v ABUS system is the only ultrasound device approved for breast cancer screening in the United States as an adjunct to mammography for asymptomatic women with dense breast tissue who have not had prior breast intervention.
One study, published in the New England Journal of Medicine, showed mammography sensitivity is reduced by 36 to 38 percent in women with dense breasts, as density masks the appearance of tumors (Boyd, et al, NEJM 2007:356:227-36M). As breast density goes up, the accuracy of mammograms goes down.
“We needed additional screening tools to improve breast cancer detection in women with dense breasts and ABUS has been proven to be beneficial and is easy to use,” said Marc Inciardi, M.D., breast imaging radiologist, University of Kansas Cancer Center in Kansas City, Mo. and consultant, GE Healthcare. “Enhancing our breast imaging capabilities without increasing the radiation dose, ABUS has quickly become a useful supplementary breast cancer detection tool in our practice.”
For more information: www.gehealthcare.com, www.klasresearch.com
July 29, 2024 
